Car T-Cell Therapy

NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.

In this edition, fludarabine has been placed on the FDA’s drug shortage list; epcoritamab is approved for advanced lymphoma; pembrolizumab with chemotherapy improves OS in gastric cancer, and more.

The treatment landscape of lymphoma has expanded rapidly within the last year, including recent FDA approvals and new designations of drugs in the pipeline.

Treatment regimens for diffuse large B-cell lymphoma have seen many recent advancements, thanks in large part to the development of targeted agents.

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.